Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Update

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 431,000 shares, a drop of 96.2% from the May 31st total of 11,270,000 shares. Currently, 10.8% of the shares of the stock are sold short. Based on an average trading volume of 60,000 shares, the short-interest ratio is presently 7.2 days.

Analyst Ratings Changes

ATRA has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, May 22nd. StockNews.com initiated coverage on shares of Atara Biotherapeutics in a research report on Wednesday. They issued a “hold” rating for the company.

Insider Transactions at Atara Biotherapeutics

In other news, EVP Anhco Nguyen sold 1,715 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.50, for a total transaction of $26,582.50. Following the completion of the transaction, the executive vice president now directly owns 35,939 shares of the company’s stock, valued at approximately $557,054.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Anhco Nguyen sold 1,715 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.50, for a total transaction of $26,582.50. Following the completion of the sale, the executive vice president now owns 35,939 shares in the company, valued at approximately $557,054.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Pascal Touchon sold 3,260 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $15.50, for a total transaction of $50,530.00. Following the sale, the chief executive officer now owns 73,165 shares of the company’s stock, valued at approximately $1,134,057.50. The disclosure for this sale can be found here. In the last three months, insiders sold 6,120 shares of company stock valued at $94,860. Company insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Atara Biotherapeutics

Institutional investors have recently modified their holdings of the business. Delap Wealth Advisory LLC acquired a new stake in shares of Atara Biotherapeutics during the 1st quarter worth approximately $29,000. Vontobel Holding Ltd. acquired a new stake in shares of Atara Biotherapeutics during the 4th quarter worth approximately $41,000. Josh Arnold Investment Consultant LLC grew its position in shares of Atara Biotherapeutics by 17.6% during the 3rd quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock worth $300,000 after buying an additional 30,000 shares during the period. Harbor Capital Advisors Inc. boosted its stake in Atara Biotherapeutics by 368.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 208,827 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 164,206 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 86,842 shares during the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Trading Up 2.9 %

ATRA opened at $8.50 on Friday. The stock has a market capitalization of $40.97 million, a PE ratio of -0.16 and a beta of 0.54. Atara Biotherapeutics has a 1-year low of $4.96 and a 1-year high of $63.38. The firm has a 50-day moving average price of $14.06 and a two-hundred day moving average price of $16.14.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($5.75) EPS for the quarter, topping the consensus estimate of ($9.25) by $3.50. Atara Biotherapeutics had a negative net margin of 671.70% and a negative return on equity of 783.31%. The company had revenue of $27.36 million during the quarter, compared to analysts’ expectations of $27.00 million. On average, research analysts predict that Atara Biotherapeutics will post -15.75 EPS for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.